New and Emerging Options in Osteoporosis: Improving Strategies and Outcomes in Practice

Chicago, IL US

Monday, March 19, 2018 | McCormick Place South Room S100A | Registration/Dinner: 6:00 – 6:30 pm | Program: 6:30 – 9:00 pm

This course is a live CME-certified Ancillary Symposium presented at Endocrine Society Anual Meeting (ENDO) 2018, held in Chicago, IL.This educational activity is supported by an independent medical educational grant from Amgen. ENDO 2018 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).




Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:
  • Describe existing clinical challenges in the diagnosis and management of osteoporosis and identify common barriers in management
  • Apply current guidelines and state of care methods when assessing and treating patients at risk for low trauma fractures or living with osteoporosis
  • Interpret the mechanism of action, benefits, and limitations of emerging osteoporosis therapies, and recognize the potential impact of current trials on practice

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 2.50 ABIM MOC
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
Course expires: 
McCormick Place South Room S100A
2301 S King Dr
Chicago, IL 60616
United States
Program Chair

John P. Bilezikian, MD, PhD (hon) - Program Chair
Dorothy L. and Daniel H. Silberberg Professor of Medicine
Vice Chair, International Education and Research
Chief, Emeritus, Division of Endocrinology
College of Physicians and Surgeons, Columbia University
New York, New York


Richard Eastell, MD, FRCP, FRCPath, FMedSci
Professor of Bone Metabolism
Head of the Academic Unit of Bone Metabolism
Director of the Mellanby Centre for Bone Research
Metabolic Bone Centre
Northern General Hospital
University of Sheffield
Sheffield, United Kingdom

Benjamin Zev Leder, MD
Massachusetts General Hospital, Boston, MA

Bart L. Clarke, MD
Professor of Medicine
Mayo Clinic
Rochester, MN


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships during the content development process for this activity:

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
John P. Bilezikian: Advisor Group, Shire, Radius, Ultragenyx, Amgen; Ad Hoc Consultant: Lilly. 
Richard Eastell, MD, FRCP, FRCPath, FMedSci: Consulting Fee, Amgen Inc, Alexion Pharmaceuticals, Inc. Grant Recipient, Amgen Inc, Alexion Pharmaceuticals, Inc., Immunodiagnostic Systems
Benjamin Zev Leder, MD: Advisory Board Member, Amgen Inc., Radius Health, Inc. Grant Recipient, Amgen Inc, Lilly USA, LLC
Bart L. Clarke, MD: Consultant, Amgen Inc.; Bristol-Myers Squibb; Research support, Shire

The following SPC member who planned and reviewed content for this activity reported  relevant financial relationships: 
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire

The following SPC members reported relevant financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire
Alan Kelly, MD: Speaker, Eli Lilly
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Amy Rothberg, MD, Susmeeta Sharma, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Click "Start" to complete meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™ and 2.5 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions about content or obtaining CME credit, please contact the Endocrine Society at


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


Review your Diplomate ABIM ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 2.50 ABIM MOC
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation